Alzamend Neuro (ALZN)
(Delayed Data from NSDQ)
$2.09 USD
-0.20 (-8.73%)
Updated Aug 7, 2024 03:51 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALZN 2.09 -0.20(-8.73%)
Will ALZN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALZN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ALZN
Alzamend Neuro partners with Massachusetts General Hospital
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer?s Disease
Alzamend Neuro and Mass General team for trial of AL001 for Alzheimer's
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study